Clinical Trials Browser

INDUSTRY × Taxes × Gynecologic × Clear all

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT05383482 2025-11-17

Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1

Phase 1/2 Completed

22 enrolled

GastrointestinalGynecologic

Uterine Cervical Neoplasms, Esophageal Neoplasms, Endometrial Neoplasms

NCT05092360 2025-08-28

ARTISTRY-7

Phase 3 Terminated

456 enrolled 19 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04731467 2024-12-27

A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors

Phase 1/2 Completed

79 enrolled

DermatologicEndocrineGastrointestinalGynecologicHead & NeckThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms

NCT03719326 2024-05-24

A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies

Phase 1 Completed

35 enrolled

BreastGynecologic

Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT02762981 2022-12-06

Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors

Phase 1/2 Completed

85 enrolled 24 charts

BreastGastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

NCT00883116 2017-03-09

IXAMPLE2

Phase 3 Terminated

551 enrolled 13 charts

Gynecologic

Endometrial Neoplasms

Clinical Trials

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1

ARTISTRY-7

A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors

A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies

Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors

IXAMPLE2